Comparative Pharmacology
Head-to-head clinical analysis: NITROFURAZONE versus TRIVAGIZOLE 3.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NITROFURAZONE versus TRIVAGIZOLE 3.
NITROFURAZONE vs TRIVAGIZOLE 3
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nitrofurazone is a nitrofuran antibacterial agent that acts by inhibiting bacterial DNA synthesis and repair through reductive activation of the nitrofuran group. It disrupts bacterial enzymes involved in carbohydrate metabolism and inhibits acetylcoenzyme A formation.
Terconazole is an imidazole antifungal agent that inhibits fungal cytochrome P450 14α-demethylase, disrupting ergosterol synthesis and fungal cell membrane integrity.
Nitrofurazone is not systemically administered; it is used topically. For topical application, apply a thin layer to the affected area 1-2 times daily, as directed by a physician.
One vaginal tablet (200 mg) inserted intravaginally at bedtime for 3 consecutive days.
None Documented
None Documented
0.3–0.5 hours (rapid metabolism and excretion; clinically short duration requires frequent dosing for local infections).
Terminal elimination half-life is approximately 7-9 hours in healthy adults, allowing for twice-daily dosing. In patients with hepatic impairment, half-life may be prolonged up to 18 hours, requiring dose adjustment.
Renal: ~80% (glomerular filtration and tubular secretion); Fecal: ~10% (biliary excretion); Hepatic metabolism: ~10%.
Renal excretion accounts for approximately 70-80% of the administered dose, with about 20% excreted as unchanged drug and the remainder as metabolites. Fecal excretion is minimal (<5%).
Category C
Category C
Antibacterial
Antibacterial/Antifungal Combination